Scientists have successfully used artificial intelligence to create a new drug regime for children with a deadly form of brain cancer that has not seen survival rates improve for more than half a century. The Guardian reports: The breakthrough, revealed in the journal Cancer Discovery, is set to usher in an "exciting" new era where AI can be harnessed to invent and develop new treatments for all types of cancer, experts say. Computer scientists and cancer specialists at the ICR and the Royal Marsden NHS Foundation Trust used AI to work out that combining the drug everolimus with another called vandetanib could treat diffuse intrinsic pontine glioma (DIPG), a rare and fast-growing type of brain tumor in children. Currently, DIPG and other similar types of tumors are incredibly difficult to remove surgically from children because they are diffuse, which means they do not have well-defined borders suitable for operations. But after crunching data on existing drugs, the team found everolimus could enhance vandetanib's capacity to "sneak" through the blood-brain barrier and treat the cancer.

The combination has proved effective in mice and has now been tested in children. Experts now hope to test it on a much larger group of children in major clinical trials. The research found that combining the two drugs extended survival in mice by 14% compared with those receiving a standard control treatment. Both the drugs in the research, which was funded by Brain Research UK, the DIPG Collaborative, Children with Cancer UK and the Royal Marsden Cancer Charity, among others, are already approved to treat other types of cancer. "The AI system suggested using a combination of two existing drugs to treat some children with DIPG -- one to target the ACVR1 mutation, and the other to sneak the first past the blood brain barrier," said Chris Jones, professor of paediatric brain tumor biology at the ICR. "The treatment extended survival when we tested it in a mouse model, and we have already started testing it out in a small number of children. We still need a full-scale clinical trial to assess whether the treatment can benefit children, but we've moved to this stage much more quickly than would ever have been possible without the help of AI."

Impossible Foods' latest meatless product is set to hit tables from Thursday: plant-based pork that claims to be tastier and healthier than the real deal. CNBC reports: The ground pork product will first be available in restaurants in the U.S., Hong Kong and Singapore, with further plans for retail expansion in those markets in the coming months. It marks the California-based company's third commercial launch after ground beef and chicken nuggets as it seeks to solidify its position in the growing plant-based protein space.

Speaking in a first-on interview ahead of the launch, Impossible Foods' president Dennis Woodside told CNBC's "Squawk Box Asia" that the pork alternative could beat the real deal in both taste and nutritional value. "Pig typically isn't regarded as a healthy product, but here you have a substitute that tastes just as good but is actually better for you," he said. According to the company, the product -- which is made primarily from soy -- provides the same amount of protein as its traditional meat counterpart, but with no cholesterol, one-third less saturated fat, and far fewer calories. Meantime, in a recent blind taste test conducted by Impossible Foods, it found that the majority (54%) of Hong Kong consumers said they preferred the meatless pork product.

A key Centers for Disease Control and Prevention advisory group unanimously voted Thursday to recommend distributing Pfizer and BioNTech's Covid-19 booster shots to older Americans and nursing home residents, clearing the way for the agency to give the final OK as early as this evening. CNBC reports: The agency's Advisory Committee on Immunization Practices specifically endorsed giving third Pfizer shots to people 65 and older in the first of four votes. The panel will also vote on whether to recommend the shots for adults with medical conditions that put them at risk of severe disease and those who are more frequently exposed to the virus -- possibly including people in nursing homes and prisons, teachers, front-line health employees and other essential workers. The elderly were among the first groups to get the initial shots in December and January.

The vote is seen as mostly a win for President Joe Biden, whose administration has said it wants to give booster shots to all eligible Americans 16 and older as early as this week. While the CDC panel's recommendation doesn't give the Biden administration everything it wanted, boosters will still be on the way for millions of Americans. The endorsement comes a day after the Food and Drug Administration granted emergency use authorization to administer third Pfizer shots to many Americans six months after they complete their first two doses. While the CDC's panel's recommendation isn't binding, Director Dr. Rochelle Walensky is expected to accept the panel's endorsement shortly.

ytene writes: As reported by CNBC, the US Court of Federal Claims has released a redacted version of the lawsuit, filed by Jeff Bezos' Blue Origin, in a complaint against NASA. Earlier this year, the agency had awarded a $2.9 billion contract to SpaceX for the design and development of a lunar lander.

Although NASA has a long history of awarding contracts to promote innovation and competition, the Blue Origin suit seemed a little unusual given the company's current lack of launch experience (they have completed numerous successful tests, including a high-altitude "edge of space" flight for Bezos, his brother and guests, but have yet to place any vehicle in orbit, let alone establish a credible, commercial space flight presence).

As was also reported by CNBC, the Government Accountability Office conducted an investigation in to the initial Blue Origin complaint, after NASA suspended the process, but found no evidence that NASA awarded the contract incorrectly and denied the initial Blue Origin complaint.

sciencehabit shares a report from Science Magazine: Mammals from mice to monkeys have tails. But humans and our cousins the great apes lack them. Now, researchers may have unearthed a simple genetic change that led to our abbreviated back end: an itinerant piece of DNA -- in a gene known as TBTX -- that leapt into a new chromosomal home and changed how great apes make a key developmental protein. The finding also suggests the genetic shift came with a less visible and more dangerous effect: a higher risk of birth defects involving the developing spinal cord.

Mice carrying both copies of the shortened gene didn't survive, but those with one long and one short version were born with a variety of tail lengths -- from none at all to nearly normal. That suggests the shorter version of the gene interferes with tail development. Because the genetically altered mice had a mix of tail lengths, other genes must be working together to eliminate all tail development in apes and humans, but the ape-specific change "was likely a critical event" about 25 million years ago as great apes diverged from other simians.

The genetically modified mice also had unusually high levels of neural tube problems, defects in the developing spinal cord. Such birth defects, which produce spina bifida, where the spinal cord doesn't close, and anencephaly, where parts of the brain and skull are missing, are fairly common in humans, affecting as many as one in 1,000 newborns. "We apparently paid a cost for the loss of the tail, and we still feel the echoes," says one author. "We must have had a clear benefit for losing the tail, whether it was improved locomotion or something else." The researchers reported their findings in a preprint posted last week on bioRxiv.

After weeks of internal strife at the Food and Drug Administration, the agency on Wednesday authorized people over 65 who had received Pfizer-BioNTech's coronavirus vaccine to get a booster shot at least six months after their second injection. The New York Times reports: The F.D.A. also authorized booster shots for adult Pfizer-BioNTech recipients who are at high risk of becoming severely ill with Covid-19 or are at risk of serious complications from the disease due to frequent exposure to the coronavirus at their jobs. The authorization sets up what is likely to be a staggered campaign to deliver the shots, starting with the most vulnerable Americans. It opens the way for possibly tens of millions of vaccinated people to receive boosters at pharmacies, health clinics, doctors' offices and elsewhere. Roughly 22 million Americans are at least six months past their second dose of the Pfizer-BioNTech vaccine, according to the Centers for Disease Control and Prevention. About half of them are 65 and older. Millions of Americans who received the Moderna and Johnson & Johnson vaccines are still waiting to learn whether they, too, can get boosters.

The F.D.A.'s decision will be followed as soon as Thursday by a recommendation from the C.D.C., which issues guidance on vaccine policy for clinicians and public health officials throughout the United States. An advisory committee of the C.D.C. is now in the midst of a two-day meeting on the issue. But even if the C.D.C. takes a different stance, health care providers are now authorized to offer third shots to Pfizer-BioNTech recipients who meet the F.D.A.'s eligibility criteria. The ruling followed weeks of internal disagreement at the F.D.A., where some vaccine regulators openly challenged the idea of offering booster shots to the general population. Public health experts and state officials have criticized what they said were confusing public messages from the Biden administration about who should be eligible for a booster shot and when.

Jeff Bezos on Monday pledged to give away $1 billion in grants this year with a focus on conservation efforts. "Nature is our life support system and it's fragile," Bezos said Monday at an event in New York City. "I was reminded of this just this July when I went into space with Blue Origin. I'd heard that seeing the Earth from space changes one's point of view of the world, but I was not prepared for just how much that would be true." CNBC reports: The pledge comes through the Bezos Earth Fund, which the Amazon founder and chairman started in 2020 to execute his $10 billion commitment to fight climate change. The Bezos Earth Fund has pledged to donate about $1 billion a year to activists, scientists and other groups working to address the globe's climate crisis, with a goal of spending $10 billion by 2030. Following this year's focus on conservation, the fund said that in the coming years it intends to support efforts around landscape restoration and food system transportation.

The latest round of grants will be used to "create, expand, manage and monitor protected and conserved areas," the Bezos Earth Fund said in a release. To start, the fund plans to focus on Central Africa's Congo Basin, the tropical Andes region and the tropical Pacific Ocean, all of which are key areas for biodiversity and carbon stocks, or the amount of carbon stored in things such as vegetation, soils and oceans. "The natural world is not better today than it was 500 years ago, when we enjoyed unspoiled forests, clean rivers and the pristine air of the pre-industrial age," Bezos said in a statement. "We can and must reverse this anomaly." It is not yet known which organizations will receive the grants. The gifts will be prioritized in areas where local communities and Indigenous peoples are a main focus of conservation programs, among other considerations, the Bezos Earth Fund said.

An anonymous reader quotes a report from Phys.Org: A relatively new type of computing that mimics the way the human brain works was already transforming how scientists could tackle some of the most difficult information processing problems. Now, researchers have found a way to make what is called reservoir computing work between 33 and a million times faster, with significantly fewer computing resources and less data input needed. In fact, in one test of this next-generation reservoir computing, researchers solved a complex computing problem in less than a second on a desktop computer. Using the now current state-of-the-art technology, the same problem requires a supercomputer to solve and still takes much longer, said Daniel Gauthier, lead author of the study and professor of physics at The Ohio State University. The study was published today in the journal Nature Communications.

Reservoir computing is a machine learning algorithm developed in the early 2000s and used to solve the "hardest of the hard" computing problems, such as forecasting the evolution of dynamical systems that change over time, Gauthier said. Previous research has shown that reservoir computing is well-suited for learning dynamical systems and can provide accurate forecasts about how they will behave in the future, Gauthier said. It does that through the use of an artificial neural network, somewhat like a human brain. Scientists feed data on a dynamical network into a "reservoir" of randomly connected artificial neurons in a network. The network produces useful output that the scientists can interpret and feed back into the network, building a more and more accurate forecast of how the system will evolve in the future. The larger and more complex the system and the more accurate that the scientists want the forecast to be, the bigger the network of artificial neurons has to be and the more computing resources and time that are needed to complete the task.

In this study, Gauthier and his colleagues [...] found that the whole reservoir computing system could be greatly simplified, dramatically reducing the need for computing resources and saving significant time. They tested their concept on a forecasting task involving a weather system developed by Edward Lorenz, whose work led to our understanding of the butterfly effect. Their next-generation reservoir computing was a clear winner over today's state-of-the-art on this Lorenz forecasting task. In one relatively simple simulation done on a desktop computer, the new system was 33 to 163 times faster than the current model. But when the aim was for great accuracy in the forecast, the next-generation reservoir computing was about 1 million times faster. And the new-generation computing achieved the same accuracy with the equivalent of just 28 neurons, compared to the 4,000 needed by the current-generation model, Gauthier said. An important reason for the speed-up is that the "brain" behind this next generation of reservoir computing needs a lot less warmup and training compared to the current generation to produce the same results. Warmup is training data that needs to be added as input into the reservoir computer to prepare it for its actual task.

FallOutBoyTonto shares a report from Ars Technica: A US intelligence officer traveling in India earlier this month with CIA director William Burns reported experiencing a mysterious health incident and symptoms consistent with so-called Havana syndrome, according to a report by CNN. The officer received immediate medical care upon returning to the US. The case raises fears that such incidents are not only increasing, but potentially escalating, unnamed officials told CNN and The New York Times. The new incident within Burns' own team reportedly left the CIA chief "fuming" with anger.

The director's schedule is tightly guarded, and officials do not know if the affected intelligence officer was targeted because the officer was traveling with the director. If the health incident was an attack carried out by an adversarial intelligence agency -- as feared -- it's unclear how the adversarial agency learned of the trip and was able to prepare an attack. It's also possible, however, that the officer was targeted for other reasons and without knowledge that the officer was traveling with the director. The report notes that this incident is the second high-profile case in less than a month. "On August 24, another so-called 'anomalous health incident' affecting US embassy staff in Hanoi, Vietnam, came to light," reports Ars Technica. "It is still unclear how many staff members were affected in that incident, but NBC News reported that two US personnel were medevaced out of the country."

Apple is working on ways to help detect and diagnose conditions such as depression, anxiety and cognitive decline using an iPhone, WSJ is reporting. Techcrunch: Researchers hope that analysis of data such as mobility, sleep patterns and how people type could spot behaviors associated with those conditions, according to The Wall Street Journal. ther measurements could include facial expression analysis and heart and respiration rates. All of the processing would take place on the device, with no data sent to Apple servers. The company is working on research projects that could lead to the development of these features. The University of California, Los Angeles, is studying stress, anxiety and depression, with Apple Watch and iPhone data for 3,000 volunteers being tracked in a study that starts this year. A pilot phase that began in 2020 recorded data from 150 participants.

The National Aeronautics and Space Administration plans to retire the International Space Station by the end of this decade, so the U.S. space agency is turning to private companies to build new space stations in orbit -- and expects to save more than $1 billion annually as a result. CNBC reports: NASA earlier this year unveiled the Commercial LEO Destinations project, with plans to award up to $400 million in total contracts to as many as four companies to begin development on private space stations. In response to NASA's request, director of commercial spaceflight Phil McAlister told CNBC that the agency "received roughly about a dozen proposals" from a variety of companies for contracts under the project. "We got an incredibly strong response from industry to our announcement for proposals for commercial, free fliers that go directly to orbit," McAlister said. "I can't remember the last time we got that many proposals [in response] to a [human spaceflight] contract announcement."

The ISS is more than 20 years old and costs NASA about $4 billion a year to operate. The space station is approved to operate through the end of 2024, with a likely lifespan extension to the end of 2028. But, moving forward, McAlister says that NASA wants "to be just one of many users instead of the primary sponsor and infrastructure supporter" for stations in low Earth orbit. "This strong industry response shows that our plan to retire the International Space Station in the latter part of this decade and transition to commercial space destinations is a viable, strong plan," McAlister said. "We are making tangible progress on developing commercial space destinations where people can work, play, and live," McAlister added. NASA is now evaluating the proposals, and McAlister said the agency hopes to announce the contract winners "before the end of the year," although he is "pushing for earlier." NASA "will not need anything near as big and as capable" as the ISS moving forward, said McAlister. He said the private space stations "could be very large, but NASA will only be paying for the part that we need."

An anonymous reader quotes a report from Ars Technica: Small doses of Pfizer's COVID-19 mRNA vaccine in children ages 5 to 11 appeared to produce strong antibody responses and comparable side effects to those seen in older age groups, according to the first top-line results from a Phase 2/3 clinical trial released by Pfizer and its partner BioNTech early Monday. The trial data involved 2,268 children ages 5 to 11 years, and these children were given a series of two 10-microgram doses of the vaccine, 21 days apart. The dosage is just a third of the 30-microgram doses given to people ages 12 and above. One month after the second dose, researchers measured the children's levels of antibodies able to neutralize the SARS-CoV-2 virus in a lab experiment. The geometric mean titer of antibody in the 5 to 11 year olds was 1,197.6 (95 percent confidence interval of 1,106.1 to 1,296.6), which is comparable to the geometric mean titer of 1,146.5 seen in people ages 16 to 25. Pfizer described the vaccine as being well tolerated in children, with side effects generally comparable to what's seen in people ages 16 to 25. But the company did not provide further data on the side effects. It also did not provide any further data on vaccine efficacy, though experts expect that comparable neutralizing antibody levels will provide comparable levels of protection against infection, hospitalization, and death. The company said it plans to submit the data to the FDA as soon as possible. It also aims to submit the data for emergency use authorization to the FDA by the end of the month. "Once data is submitted to the FDA, it will take regulators several weeks to review the data and make a decision," the report adds. "That places the earliest estimates for vaccine authorization and availability for the 5-to-11 group at the end of October."

The U.S. death toll from COVID-19 has surpassed that of the 1918 flu pandemic, according to a tracker from Johns Hopkins University. The Hill reports: The U.S. has passed 675,000 deaths, the estimated toll from the 1918 pandemic, which for a century had been the worst pandemic to hit the country. "The number of reported deaths from Covid in the US will surpass the toll of the 1918 flu pandemic this month," Tom Frieden, the former head of the Centers for Disease Control and Prevention, tweeted earlier this month. "We cannot become hardened to the continuing, and largely preventable, tragedy."

Deaths from COVID-19 are also far from over. The U.S. is averaging about 2,000 more deaths from the virus every day, according to a New York Times tracker. Those deaths are overwhelmingly among the unvaccinated, though, highlighting that the continuing toll of COVID-19 is now largely preventable now that vaccines are widely available in the U.S. In 1918, there was no vaccine to help stop the flu pandemic. Still, the U.S. population was far smaller a century ago, meaning that the death rate from the 1918 pandemic is still higher than for COVID-19. E. Thomas Ewing, a Virginia Tech history professor, wrote in Health Affairs earlier this year that the death rate from the 1918 pandemic was about six in every 1,000 people, given the U.S. population at the time of around 100 million. The death rate from COVID-19 in the U.S. is about two in every 1,000 people. A disproportionate share of COVID-19 deaths are also in the United States. Worldwide, the 1918 flu killed far more people than COVID-19 has so far, at about 50 million compared to about 5 million.

Oregon Health & Science University reported Friday that in the 45 days before September 14, five Oregonians had to be hospitalized "because they consumed a potent antiparasitic drug despite there being no clinical data supporting its use for COVID-19...

"Two people were so severely ill that they had to be admitted to an intensive care unit." The Oregon Poison Center has managed 25 cases involving Oregonians intentionally misusing ivermectin to treat or prevent COVID-19 between Aug. 1 and Sept. 14... The Oregon Poison Center's recent cases involved a variety of symptoms, including mental confusion, balance issues, low blood pressure and seizure. The patients were in their 20s through their 80s, although most were older than 60. The cases were fairly evenly split between both men and women, and between people attempting to either prevent or treat COVID-19. Some cases involved individuals obtaining a prescription for either human or veterinary forms of the drug.

Both the Food and Drug Administration and Merck, which makes ivermectin for human use, have announced there is no scientific data that supports its use for COVID-19. Neither the FDA nor the National Institutes of Health have endorsed its use for COVID-19, and OHSU doesn't recommend any use of ivermectin for COVID-19.
They add that "The Oregon Poison Center strongly recommends the public only use scientifically proven and FDA-approved methods to combat the novel coronavirus."

But there's also been more hospitalizations from ivermectin overdoses in other states, reports the Arizona Republic. Banner Health, a 50,000-employee health non-profit managing 30 hospitals in six states (and staffing a local poison control hotline) reports that their "Poison and Drug Information Center" received at least 30 calls this year, including 10 in August, and "at least seven cases have resulted in hospitalization, health system officials said." "That is the bare minimum. We expect that there are probably more adverse effects," said Dr. Daniel Brooks, medical director for Banner Health's Poison and Drug Information Center. "We are very concerned that people are using this medication inappropriately because we don't know what dose they are using. We don't even know what product they are getting their hands on..." ivermectin has side effects in up to 10% of people who are treated with it, Brooks said. Side effects can include diarrhea, confusion, nausea, vomiting, balance problems and blurred vision...

"If they have side effects, then they could end up in the emergency department, further overwhelming the health system in Arizona and the rest of the United States and potentially getting COVID from sitting in a busy emergency department waiting room, or being admitted to the hospital because of ongoing nausea and vomiting."
And even in the same state, other organizations also reported more hospitalizations from ivermectin overdoses. "The University of Arizona's Arizona Poison and Drug Information Center, which has had 19 reports related to ivermectin so far this year, including eight who were hospitalized, center director Steve Dudley wrote in an email."

A Pennsylvania newspaper tracked down Dr. Kenneth Brown — who wrote Merck's original research protocols in the 1980s for studying ivermectin as a "river blindness" treatment.

They describe Brown as 85 years old, retired, and "proud of his association with Ivermectin." More than 4 billion doses of ivermectin (renamed Mectizan) have been administered globally in the effort to eliminate river blindness, the leading cause of preventable blindness worldwide. Historically, river blindness — transmitted by the bites of black flies that breed near rivers and streams — is prevalent in 36 countries in Africa, Latin America and Yemen. Brown saw firsthand in west Africa the miracle at work, often administered by local townspeople — who could neither read nor write — trained through Merck's donation program.

"We want to celebrate Ivermectin for what it's done around the world," said Polly Ann Brown, Brown's wife.
They asked how he feels about people "willing to bypass evidence...collected through traditional scientific studies" to try self-administering their own levels of the drug in home experiments seeking remedies for Covid-19. (The article notes that even the author of an often-cited Australian study that initially claimed a benefit from ivermectin has since said "[T]he potential repurposing plausibility if any is at present not very likely, because the antiviral concentrations would be attainable only after massive overdose.") Brown tracks questionable claims about medicines as a retirement job... The main thrust of many pushing the use of ivermectin [as an unproven Covid-19 treatment] goes something like this: Big pharma doesn't want the public to use ivermectin...because the pharmaceutical companies don't make vast sums of money on what is, essentially in the U.S., a horse dewormer. Billions of people — they will argue — have taken the drug safely.

What they don't say, or don't know, is that ivermectin has been administered billions of times. But because ivermectin is not a one-and-done treatment (it has to be administered once annually) that's an exaggeration. And while it's been used for decades, there are no established safety protocols for its use as a COVID-19 treatment. The way Brown sees it, the affection for ivermectin rather than one of the COVID-19 vaccines authorized for use in the U.S. reveals an anti-science bias.

Brown's advice?

"Don't get your information or medical advice from Facebook or Instagram," Brown said. "No social media can be reliably accurate."
Elsewhere in the article, Brown stresses that Ivermectin is "not magic..."

"It is a danger to trust the dream we wish for rather than the science we have.'

"The whitest paint in the world has been created in a lab at Purdue University," reports USA Today, "a paint so white that it could eventually reduce or even eliminate the need for air conditioning, scientists say.

"The paint has now made it into the Guinness World Records book as the whitest ever made."

Long-time Slashdot reader phalse phace shared their report: "When we started this project about seven years ago, we had saving energy and fighting climate change in mind," said Xiulin Ruan, a professor of mechanical engineering at Purdue, in a statement. The idea was to make a paint that would reflect sunlight away from a building, researchers said. Making this paint really reflective, however, also made it really white, according to Purdue University. The paint reflects 98.1% of solar radiation while also emitting infrared heat.

Because the paint absorbs less heat from the sun than it emits, a surface coated with this paint is cooled below the surrounding temperature without consuming power. Using this new paint to cover a roof area of about 1,000 square feet could result in a cooling power of 10 kilowatts. "That's more powerful than the air conditioners used by most houses," Ruan said. Typical commercial white paint gets warmer rather than cooler. Paints on the market that are designed to reject heat reflect only 80% to 90% of sunlight and can't make surfaces cooler than their surroundings...

Researchers at Purdue have partnered with a company to put this ultra-white paint on the market, according to a news release.
"This white paint is the result of research building on attempts going back to the 1970s," adds a statement from Purdue University, "to develop radiative cooling paint as a feasible alternative to traditional air conditioners.

"Ruan's lab had considered over 100 different materials, narrowed them down to 10 and tested about 50 different formulations for each material..." Two features make this paint ultra-white: a very high concentration of a chemical compound called barium sulfate — also used in photo paper and cosmetics — and different particle sizes of barium sulfate in the paint. What wavelength of sunlight each particle scatters depends on its size, so a wider range of particle sizes allows the paint to scatter more of the light spectrum from the sun.

Watch the video here!

"SpaceX safely returned its Crew Dragon spacecraft from orbit on Saturday, with the capsule carrying the four members of the Inspiration4 mission back to Earth after three days in space..." reports CNBC: "Thanks so much SpaceX, that was a heck of a ride for us and we're just getting started!" Inspiration4 commander Jared Isaacman said from the capsule after touching down.

Elon Musk tweeted his congratulations to the crew shortly after splashdown.

The historic private mission — which includes Isaacman, pilot Sian Proctor, medical officer Hayley Arceneaux and mission specialist Chris Sembroski — orbited the Earth at an altitude as high as 590 kilometers, which is above the International Space Station and the furthest humans have traveled above the surface in years. A free-flying spaceflight, the capsule did not dock with the ISS but instead circled the Earth independently at a rate of 15 orbits per day.

Inspiration4 shared photos from the crew's time in orbit, giving a look at the expansive views from the spacecraft's "cupola" window.

This is the third time SpaceX has returned astronauts from space, and the second time for this capsule — which previously flew the Crew-1 mission for NASA on a trip that returned in May.

"A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing," reports Fierce Biotech: We don't like to throw the word "cure" around here. But Excision BioTherapeutics thinks the therapy could replace standard-of-care retroviral therapy, which keeps HIV from replicating but does not remove it from the body. That means patients stay on the treatment, which can cause serious side effects and affect quality of life. Now with the start of human testing, the real path to see if this new and lauded tech can accomplish this really begins.

HIV integrates its genetic material into the genome of a host cell, meaning available therapies just can't remove it. A team of scientists at Temple University and the University of Nebraska Medical Center managed to remove the virus completely from mice during preclinical testing using a combination of CRISPR and antiretroviral therapy. They also found no adverse events that could be linked to the therapy in the study, published back in 2019... EBT-101 has since been tested in nonhuman primates, which showed it reached every tissue in the body where HIV reservoirs reside.

Excision licensed the therapy from the universities with a goal of moving it into clinical trials. Now, the FDA is on board. The biotech plans to initiate a phase 1/2 clinical trial later this year, according to the statement.

The technology used by Excision was licensed from the lab of famed CRISPR pioneer Jennifer Doudna. The company is also working on similar treatments for other viruses, including herpes and hepatitis B.

An anonymous reader quotes a report from Fast Company: [R]esearchers in Finland are experimenting with growing coffee from plant cells in bioreactors. There are several reasons why it might make sense to have such an alternative, says Heiko Rischer, a research team leader at VTT Technical Research Centre of Finland, the state-owned organization developing the coffee. "Conventional coffee production is notoriously associated with several problematic issues, such as unsustainable farming methods, exploitation, and land rights," he says. "Growing demand and climate change add to the problems." In Vietnam, for example, coffee production is driving deforestation.

The researchers are using the same techniques to make coffee that others are using to make "lab-grown," or cultivated, meat. Coffee plant cells were cultured in the lab, and then placed in bioreactors filled with nutrient medium to grow. It's a little easier to grow coffee than something like beef. "The nutrient media for plant-cell cultures are much less complex, i.e., cheaper, than those for animal cells," Rischer says. "Scaling up is also easier because plant cells grow freely, suspended in the medium, while animal cells grow attached to surfaces."

The process results in an off-white biomass that's dried into a powder, then roasted to a dark brown color that looks like coffee grounds. The scientists recently brewed their first cups of the lab-grown coffee, which they say tastes and smells like ordinary coffee. It's also possible to make different varieties. "Cell cultures of different coffee cultivars can be established, and the roasting process can be modified, in order to produce coffee with very different character," says Rischer. "The cultivation process can be modified in order to generate more or less of certain compounds, such as caffeine or flavors." The lab plans to work with companies that can commercialize the new process.

An anonymous reader quotes a report from CNBC: An influential Food and Drug Administration advisory committee on Friday resoundingly rejected a plan to administer booster shots of Pfizer and BioNTech's Covid-19 vaccine to the general public, saying they needed more data. The panel, however, could still recommend the shots for other populations. Scientists continued debating the need for a third dose of the vaccines for people 65 and older and other vulnerable populations after their initial vote. "It's likely beneficial, in my opinion, for the elderly, and may eventually be indicated for the general population. I just don't think we're there yet in terms of the data," Dr. Ofer Levy, a vaccine and infectious disease specialist at Boston Children's Hospital, said after voting against the original proposal. The final tally failed 16-2.

In a paper published days before the advisory committee meeting, a leading group of scientists said available data showed vaccine protection against severe disease persists, even as the effectiveness against mild disease wanes over time. The authors, including two high-ranking FDA officials and multiple scientists from the World Health Organization, argued Monday in the medical journal The Lancet that widely distributing booster shots to the general public is not appropriate at this time. In outlining plans last month to start distributing boosters as early as next week, administration officials cited three CDC studies that showed the vaccines' protection against Covid diminished over several months. Senior health officials said at the time they worried protection against severe disease, hospitalization and death "could" diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout. Before the vote, some committee members said they were concerned that there wasn't enough data to make a recommendation, while others argued third shots should be limited to certain groups, such as people over age 60 who are known to be at higher risk of severe disease. Some members raised concerns about the risk of myocarditis in younger people, saying more research is needed.